We asked whether compensatory RAS reactivation would be inhibited, and found that the addition of SHP2i to MEKi prevented RAS reactivation at 24 and 48 hours as measured by levels of GTP-bound RAS (Figure 2D), comparable to the effect seen in NF1-deficient cancer models.23 Here, NF1 is linked to cancer.